E
89bio D
D
ETNB
11.060
USD
0.09
(0.82%)
مغلق
حجم التداول
38,905
الربح لكل سهم
-3
العائد الربحي
-
P/E
-4
حجم السوق
1,587,545,344
المقالات
العنوان: 89bio
القطاع: Healthcare
الصناعة: Biotechnology
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).